Konstantinos Charitakis, MD
Basic profileThe University of Texas MD Anderson Cancer Center
Konstantinos Charitakis is a Cardiology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 100 publications with 1,994 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6410 Fannin St
Suite 600
Houston, TX 770303000
Telephone
832-325-7100Provider last certified this registry record 6 Nov 2020.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20255 payments
- Endologix LLCProgram year20251 payment
- Boston Scientific CorporationProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.3%Beta blocker19%Metoprolol Succinate47%Carvedilol38%Metoprolol Tartrate11%Sotalol3%Atenolol2%Part D<11 patientsStatin18.5%Atorvastatin Calcium67%Rosuvastatin Calcium19%Simvastatin9%Pravastatin Sodium5%Part D≥139 patients+ 16 more classes in this area
Blood & clotting
18.6%P2Y12 inhibitor10.5%Clopidogrel89%Brilinta11%Part D≥101 patientsFactor Xa inhibitor7.3%Eliquis74%Xarelto27%Part D≥50 patients+ 1 more class in this area
Metabolism & gastrointestinal
1.1%SGLT2 inhibitor0.7%Jardiance100%Part D<11 patientsPotassium supplement0.4%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Navigating P2Y12 inhibition in the labyrinth of cardio-oncology care: cangrelor bridging in patients with cancer
Frontiers in Cardiovascular Medicine
2024 - 1821–2021: Contributions of physicians and researchers of Greek descent in the advancement of clinical and experimental cardiology and cardiac surgery
Frontiers in Cardiovascular Medicine
2023 - Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents
Frontiers in Cardiovascular Medicine
2022 - Machine Learning-Augmented Propensity Score Analysis of Percutaneous Coronary Intervention in Over 30 Million Cancer and Non-cancer Patients
Frontiers in Cardiovascular Medicine
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”